Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

SAFE-LCD Trial, for Insulin-treated Adults Living With Type 2 Diabetes

A legfontosabb adatok

Ki végzi
Oviva UK Ltd
Hol
Egyesült Királyság1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Résztvevők
21 fő vett részt
Kezdés
2024. jan. 26.
Befejezés
2024. szept. 9.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Oviva programme
  • Usual care
A regiszteradat frissítve
2024. október 15.
Miért állt le
Slow recruitment

Ki vehet részt

Életkor
18 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 38 feltétel megnézéseKevesebb

Ki vehet részt

  • Registered with a GP practice within the confirmed NHS site - Humber and North Yorkshire
  • Diagnosis of type 2 diabetes treated with insulin
  • Age 18-70 years inclusive
  • BMI ≥30kg/m² (adjusted to ≥27 kg/m² in ethnic minority groups)
  • Upper body weight limit of 180kg (if using BodyTrace scales)
  • Ability to speak, read and receive care in English language
  • Access to the internet and a personal email address
  • Access to and ability to use a smartphone
  • Willing to test blood glucose up to 7 times a day (for up to 4 months) to ensure clinical safety
  • Participants capable to provide written informed consent and willing to comply with the trial protocol

Ki nem vehet részt

  • Concomitant medication use clinically deemed to affect metabolic rate and body weight
  • Warfarin or Rivaroxoban therapy
  • Active cancer, receiving cancer treatment or received cancer treatment within past 24 months
  • History of bariatric surgery (previous band/balloon allowed if removed<12 months)
  • Known or suspected alcohol or recreational drug misuse
  • Currently on a weight management programme or had in last 3 months or had over 5% weight loss in previous 6 months
  • C-peptide <200 pmol/L AND positive Glutamic Acid Decarboxylase(GAD) antibodies assessing for misdiagnosed Type 1 diabetes and risk of diabetic ketoacidosis
  • Type 1 diabetes mellitus, Mitochondrial diabetes, Maturity-Onset Diabetes of the Young (MODY) diabetes or diagnostic uncertainty (e.g. dual codes on patient record) Type 2 diabetes with history of diabetic ketoacidosis (DKA) or ketosis prone
  • A condition precipitating fluid overload (e.g. New York Heart Association class III-IV congestive heart failure)
  • Active liver disease (except non-alcoholic fatty liver disease (NAFLD)
  • Active gallstone disease or known presence of gallstones
  • Uncontrolled epilepsy
  • Active or suspected peptic ulcer disease
  • Clinically diagnosed with an active eating disorder
  • Clinically significant diagnosed/self-reported psychiatric disease that may interfere with study compliance
  • Milk allergy (Nualtra, TDR allergens)
  • Soya allergy (Nualtra, TDR allergens)
  • Severe angina, uncontrolled arrhythmia or known prolonged QT syndrome
  • Estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m²
  • Clinically assessed hypoglycemia unawareness (via GOLD score (11, 12))
  • A major cardiovascular event within 6 months
  • Known proliferative retinopathy that has not been treated
  • Uncontrolled thyroid dysfunction
  • Gout
  • Vegan (Nualtra, animal derived Vit D)
  • Pregnancy or planning pregnancy within study period
  • Lactating
  • Current participation in other clinical intervention trials

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

SAFE-LCD study is a randomised controlled trial aiming to develop and evaluate a safe, cost-effective, easily accessible, digital Low-Calorie Diet (LCD) programme for insulin-treated adults with Type 2 diabetes (T2D), a world-first innovation.

A teljes eredeti leírásKevesebb

The study plans to enrol 72 participants who will be randomly allocated to either receive the intervention or will be provided with weight loss advice suitable for insulin-treated patients through accessing the NHS 12-week weight loss plan. The intervention arm will follow Oviva Diabetes Remission Insulin (ODR-I) programme which includes expert dietitian coaching, support of a Diabetes Nurse, the Oviva app (with a 12-month weight prediction chart), a Capilar Blood Glucose (CBG) meters (for enhanced safety in view of concerns re hypo- and hyper-glycaemia), and BodyTrace weight scales.

If successful, this project will provide game-changing evidence for the support of insulin-treated T2D patients and for NHS commissioning of the digital Low-Calorie programme driving patient benefits and cost-savings.

A vizsgálat 2 csoportja

  • Intervention (Oviva ODR-I programme)A vizsgált kezelés

    The intervention arm will follow Oviva ODR-I programe: a 12-week TDR of approximately 850 calories per day through four TDR products daily, supported by the digital scales, CBG meters and link to the OVIVA app.

    Kezelés: Oviva programme

  • Control (NHS 12 weeks programme)Már használt kezelés, összehasonlításként

    The control group will follow usual care, which will be the NHS 12-week digital weight-loss programme

    Kezelés: Usual care

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Trial to Determine Safety And Efficacy of a Digital Low-Calorie Diet Programme (SAFE-LCD) for Insulin-treated Adults Living With Type 2 Diabetes
A regiszteradat frissítve
2024. október 15.